AusCann Group Holdings

AusCann Group Holdings

AusCann Group Holdings

Having recently acquired CannPal Animal Therapeutics, AusCann has taken the global leadership position in cannabinoid-based animal health with our research, development and regulatory progress. We have completed clinical trials using cannabinoids in over 140 dogs and are the only Company in the world with an INAD file open with the FDA for a veterinary drug candidate in phase 2 with THC for pain, inflammation and quality of life in dogs with osteoarthritis.

We're in an exciting growth phase as we move into the U.S and are developing a number of products within the global companion animal health market. You will be a key founding member of the U.S team launching our first product in the canine dermatology category and sold exclusively though veterinary clinics in the USA.

We offer great working conditions for work / life balance, and there's an opportunity for the candidate to get incentives like equity shares as the Company grows. But most importantly, you will feel like you're part of an exciting growth Company, and will play a key role in setting and executing on strategies to maximize market penetration for our first animal health product and be part of our new and exciting company with big goals.  
Sydney, New South Wales, Australia Sydney, New South Wales, Australia

Company Information

AusCann is an Australian-based public Company focused on the development and commercialisation of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Our key difference is the commitment to rigorous product development, focused on providing reliable, stable and standardised cannabinoid-derived therapeutics products, whilst generating robust safety, quality assurance and efficacy data to support market access in various regulatory environments around the world.

We have built a strong team of experts and partners in both human and animal health, with the right expertise across all aspects of both the pharmaceutical and nutraceutical value chains. Our immediate focus is on providing both healthcare professionals and veterinarians with solutions to optimise treatment outcomes for patients and for pets. To do that, we have developed innovative technologies to enhance the delivery of our novel formulations and aim to commercialise our products through various regulatory frameworks around the world.

Most recently, AusCann acquired CannPal Animal Therapeutics, a global leader in the development of innovative, cannabinoid-derived therapeutic products to provide veterinarians and pet owners with clinically validated and standardised therapeutics to treat animals in a safe and more natural way.

Presently, the Company is developing products containing CBD, THC and other active ingredients for registration and commercialisation as veterinary medicines and nutraceuticals in the areas of pain, inflammation, mood and dermatological skin conditions.

You can view CannPal's most recent product presentation on the Company's lead THC based Osteoarthritis drug candidate in development for FDA approval at the link below:

No job openings